UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 12, 2017
Recro Pharma, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| Pennsylvania | | 001-36329 | | 26-1523233 |
(State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | |
| 490 Lapp Road, Malvern, Pennsylvania | | 19355 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (484) 395-2470
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
On May 12, 2017, Recro Pharma, Inc. (the “Company”) held its 2017 Annual Meeting of Shareholders (the “Annual Meeting”). The following is a brief description of the final voting results for each of the proposals submitted to a vote of the shareholders at the Annual Meeting.
| (a) | Proposal 1 — Election of Class III Directors. Each of Alfred Altomari, William L. Ashton and Dr. Michael Berelowitz were elected to the Board of Directors as Class III directors to serve until the Company’s 2020 annual meeting of shareholders, as follows: |
| | | | | | | | | | |
Name | | Votes For | | Votes Withheld | | | Broker Non-Votes | |
| Alfred Altomari | | 13,157,405 | | | 508,828 | | | | 2,818,253 | |
| William L. Ashton | | 13,628,626 | | | 37,607 | | | | 2,818,253 | |
| Dr. Michael Berelowitz | | 13,628,426 | | | 37,807 | | | | 2,818,253 | |
| (b) | Proposal 2 — Ratification of Independent Registered Public Accountants. The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the 2017 fiscal year was ratified, as follows: |
| | | | | | |
Votes For | | Votes Against | | Abstentions | | Broker Non-Votes |
| 16,364,163 | | 117,164 | | 3,159 | | 0 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | |
| Recro Pharma, Inc. |
| |
| By: | | /s/ Gerri A. Henwood |
| Name: | | Gerri A. Henwood |
| Title: | | Chief Executive Officer |
Date: May 18, 2017
